TOP TEN perturbations for 38714_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38714_at
Selected probe(set): 205838_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38714_at (205838_at) across 6674 perturbations tested by GENEVESTIGATOR:

sickle cell disease study 2 (Globin red.) / normal blood sample

Relative Expression (log2-ratio):5.3181963
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Globin red.)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear™-Human kit.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit.

sickle cell disease study 2 (Pax) / normal blood sample

Relative Expression (log2-ratio):5.1016912
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Pax)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.161889
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.7762384
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(8;21)(q22;q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.5822935
Number of Samples:40 / 74
Experimental AML study 1 (t(8;21)(q22;q22))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(8;21)(q22;q22)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-3.421976
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.3321524
Number of Samples:121 / 74
Experimental c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.329587
Number of Samples:38 / 74
Experimental AML study 1 (t(11q23))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

mature B-ALL study 1 (t(8;14)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.3077822
Number of Samples:13 / 74
Experimental mature B-ALL study 1 (t(8;14))
Bone marrow samples of patients with mature B-ALL (t(8;14)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.28901
Number of Samples:36 / 74
Experimental AML study 1 (t(15;17)(q22;q11-12))
Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.